REG - Oncimmune Hldgs PLC - Change of registered office

Oncimmune HoldingsAnnouncement

26/06/2023 11:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230626:nRSZ9010Da&default-theme=true

RNS Number : 9010D  Oncimmune Holdings PLC  26 June 2023

26 JUNE 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Change of registered office

 

Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody profiling
company to the pharmaceutical and biotechnology industry, is today announcing
that its registered office has changed to 1 Park Row, Leeds, United Kingdom,
LS1 5AB.

 

 

For further information:

Oncimmune Holdings plc

Ron Kirschner, Chief Executive Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBGGDLIGDDGXL